Low- and standard-estrogen dosage in oral therapy: Dose-dependent effects on insulin and lipid metabolism in healthy postmenopausal women

Climacteric

Volumn 11, Issue 6, 2008, Pages 498-508

  Villa, P ^a   Sagnella, F ^a   Perri, C ^a   Suriano, R ^a   Costantini, B ^a   Macri, F ^a   Ricciardi, L ^a   Lanzone, A ^a,b  

^a CATHOLIC UNIVERSITY   (Italy)

^b OASI RESEARCH INSTITUTE IRCCS   (Italy)

Author keywords

Carbohydrate metabolism; Estrogen; Insulin sensitivity; Lipid metabolism; Postmenopausal women

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; ARTICLE; CARBOHYDRATE METABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; FEMALE; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INSULIN METABOLISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LOW DRUG DOSE; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

BLOOD GLUCOSE; CARBOHYDRATE METABOLISM; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INSULIN; ITALY; LIPID METABOLISM; MIDDLE AGED; REFERENCE VALUES; TRIGLYCERIDES; WOMEN'S HEALTH;

EID: 57349129546     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130802471058     Document Type: Article

References (54)

1. Proudler AJ, Felton CV, Stevenson JC. Ageing and the response of plasma insulin, glucose and C-peptide concentrations to intravenous glucose in postmenopausal women. Clin Sci 1992;83:489-94
2. Walton C, Godsland IF, Proudler AJ, et al. The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women. Eur J Clin Invest 1993;23:466-73
3. Otsuki M, Kasayama S, Morita S, et al. Menopause, but not age, is an independent risk factor for fasting plasma glucose levels in nondiabetic women. Menopause 2007;14:404-7
4. Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2003;138:1-9
5. Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of estrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health. Initiative hormone trial. Diabetologia 2004;47:1175-87
6. Godsland IF. Estrogens and insulin secretion. Diabetologia 2005;48:2213-20
7. Duncan AC, Lyall H, Roberts RN, et al. The effect of estradiol and a combined estradiol/progestagen preparation on insulin sensitivity in healthy postmenopausal women. J Clin Endocrinol Metab 1999;84:2402-7
8. Godsland IF, Manassiev NA, Felton CV, et al. Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women. Clin Endocrinol 2004;60:541-9
9. Godsland IF, Gangar K, Walton C, et al. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 1993;42:846-53
10. Karjalainen A, Paassilta M, Heikkinen J, et al. Effects of peroral and transdermal estrogen replacement therapy on glucose and insulin metabolism. Clin Endocrinol 2001;54:165-73
11. Osmanagaoglu MA, Osmanagaoglu S, Osmanagaoglu T, et al. Effect of different preparations of hormone therapy on lipid and glucose metabolism, coagulation factors, and bone mineral density in overweight and obese postmenopausal women. Fertil Steril 2005;84:384-93
12. Gambacciani M, Ciaponi M, Cappagli B, et al. Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women. Am J Obstet Gynecol 2001;185:1180-5
13. Lindsay R, Gallagher JC, Kleerekoper M, et al. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002;287:2668-76
14. Koh KK, Shin MS, Sakuma I, et al. Effects of conventional or lower doses of hormone replacement therapy in postmenopausal women. Arterioscler Thromb Vasc Biol 2004;24:1516-21
15. Lundström E, Bygdeson M, Svane G, et al. Neutral effect of ultra-low-dose continuous combined estradiol and norethisterone acetate on mammographic breast density. Climacteric 2007;10:249-56
16. Chu MC, Cosper P, Nakhuda GS, et al. A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome. Fertil Steril 2006;86:1669-75
17. Koh KK, Shin MS, Sakuma I, et al. Effects of conventional or lower doses of hormone replacement therapy in postmenopausal women. Arterioscler Thromb Vasc Biol 2004;24:1516-21
18. Wolfe BM, Huff MW. Effects of continuous low-dosage hormonal replacement therapy on lipoprotein metabolism in postmenopausal women. Metabolism 1995;44:410-17
19. Vadlamudi S, MacLean P, Israel RG, et al. Effects of oral combined hormone replacement therapy on plasma lipids and lipoproteins. Metabolism 1998;47:1222-6
20. Kernohan AF, Sattar N, Hilditch T, et al. Effects of low-dose continuous combined hormone replacement therapy on glucose homeostasis and markers of cardiovascular risk in women with type 2 diabetes. Clin Endocrinol 2007;66:27-34
21. Peeyananjarassri K, Baber R. Effects of low-dose hormone therapy on menopausal symptoms, bone mineral density, endometrium, and the cardiovascular system: a review of randomized clinical trials. Climacteric 2005;8:13-23
22. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-23
23. Mari A, Pacini G, Murphy E, et al. A modelbased method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001;24:539-48
24. Mather KJ, Hunt AE, Steinberg HO, et al. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab 2001;86:5457-64
25. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-57
26. Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocrine Rev 1985;6:45-75
27. Lanzone A, Fulghesu AM, Fortini A, et al. Effect of opiate receptor blockade on the insulin response to oral glucose load in polycystic ovarian disease. Hum Reprod 1991;6:1043-9
28. Faber OK, Christensen K, Kehlet H, et al. Decreased insulin removal contributes to hyperinsulinemia in obesity. J Clin Endocrinol Metab 1981;53:618-21
29. Grundy SM. Point: the metabolic syndrome still lives. Clin Chem 2005;51:1352-7
30. Lin KC, Tsai ST, Kuo SC, et al. Interrelationship between insulin resistance and menopause on the metabolic syndrome and its individual component among nondiabetic women in the kinmen study. Am J Med Sci 2007;333:208-14
31. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13
32. Sites CK. Hormone replacement therapy: cardiovascular benefits for aging women. Coron Artery Dis 1998;9:789-93
33. Herrington DM, Howard TD, Hawkins GA, et al. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med 2002;346:967-74
34. Gambacciani M, Ciaponi M, Cappagli B, et al. Body weight, body fat distribution, and hormonal replacement therapy in early postmenopausal women. J Clin Endocrinol Metab 1997;82:414-17
35. Salpeter SR, Walsh JM, Ormiston TM, et al. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006;8:538-54
36. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77
37. Morin-Papunen LC, Vauhkonen I, Ruokonen A, et al. Effects of tibolone and cyclic hormone replacement therapy on glucose metabolism in non-diabetic obese postmenopausal women: a randomized study. Eur J Endocrinol 2004;150:705-14
38. Cucinelli F, Paparella P, Soranna L, et al. Differential effect of transdermal estrogen plus progestagen replacement therapy on insulin metabolism in postmenopausal women: relation to their insulinemic secretion. Eur J Endocrinol 1999;140:215-23
39. Soranna L, Cucinelli F, Perri C, et al. Individual effect of E2 and dydrogesterone on insulin sensitivity in postmenopausal women. J Endocrinol Invest 2002;25:547-50
40. O'Sullivan AJ, Ho KK. A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenopausal women. J Clin Endocrinol Metab 1995;80:1783-88
41. Li C, Samsioe G, Borgfeldt C, et al. Low-dose hormone therapy and carbohydrate metabolism. Fertil Steril 2003;79:550-5
42. Matute ML, Kalkhoff RK. Sex steroid influence on hepatic gluconeogenesis and glucogen formation. Endocrinology 1973;92:762-8
43. Ahmed-Sorona H, Bailey CJ. Role of ovarian hormones in the long term control of glucose homeostasis. Horm Res 1980;13:396-403
44. Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196-204
45. Rajman I, Lip GY, Cramb R, et al. Adverse changes in low-density lipoprotein subfractions profile with estrogen-only hormone replacement therapy. Q J Med 1996;89:771-8
46. Tilly-Kiesi M, Lappi M, Puolakka J, et al. Different effects of continuous estrogenprogestin and transdermal estrogen with cyclic progestin regimens on low-density lipoprotein subclasses. Eur J Clin Invest 1996;26:1125-33
47. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen-progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial period. JAMA 1995;272:199-208
48. Moorjani S, Dupont A, Labrie F, et al. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women. J Clin Endocrinol Metab 1991;73:373-9
49. Haffner SM, Valdez RA. Endogenous sex hormones: impact on lipids, lipoproteins, and insulin. Am J Med 1995;98(Suppl 1A):40-7S
50. Davidson MH, Maki KC, Marx P, et al. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. Arch Intern Med 2000;160:3315-25
51. Scandinavian Simvastatin Survival Study group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;19:1383-9
52. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation 1997;95:69-75
53. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996;276:882-8
54. Sniderman AD, Pedersen T, Kjekshus J. Putting low-density lipoproteins at center stage in atherogenesis. Am J Cardiol 1997;79:64-7